MIRA Pharmaceuticals, Inc.
MIRANASDAQHealthcareDrug Manufacturers - General
Previous close
$0.7636
+$0.0535 · +7.53%
MIRA company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
29
Expensive
Momentum
29
Weakening
Sentiment
56
Mixed
Risk resilience
24
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteMIRA Pharmaceuticals, Inc. operates as a biopharmaceutical enterprise currently in the clinical development phase. Its main objective involves the creation and market introduction of a novel synthetic tetrahydrocannabinol (THC) analog. This compound is undergoing investigation for its potential to address anxiety and the cognitive impairments frequently observed in adult patients suffering from early-stage dementia. The firm's lead candidate, MIRA1a, is a synthetic cannabinoid analog engineered to alleviate both anxiety and chronic pain through its interaction with cannabinoid type 1 and type 2 receptors. Originally established in 2020 as MIRA1a Therapeutics, Inc., MIRA Pharmaceuticals, Inc. maintains its headquarters in Baltimore, Maryland.
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Erez Aminov
- Listed since
- Aug 3, 2023
- Employees
- 2
Market position
Day range
Current $0.7636
52-week range
Current $0.7636
- Open
- $0.72
- Previous close
- $0.7101
- Volume
- 117.4K
- 1.08× average
- Average volume
- 109.18K
- Average daily volume
- Market cap
- 32.09M USD
- Beta
- 1.55
- Market reference 1
- 50-day average
- $0.8653
- -11.75% below average
- 200-day average
- $1.1439
- -33.24% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 29.43M USD
- P/E (TTM)
- -0.55×
- P/B (TTM)
- 3.93×
- P/S (TTM)
- 0×
- EV / EBITDA
- -2.82×
- Earnings yield
- -29.19%
- Free cash flow yield
- -13.03%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- -100.49%
- Return on assets
- -94.13%
- Return on invested capital
- -100.98%
Financial health
- Debt / equity
- 0×
- Current ratio
- 15.75×
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 1.72M USD | 3.31M USD | 1.57M USD | 2.35M USD | 684.45K USD |
| Selling, general, and administrative | 8.77M USD | 4.71M USD | 6.5M USD | 2.99M USD | 770.12K USD |
| Operating expenses | 10.49M USD | 8.02M USD | 8.53M USD | 7.05M USD | 2.15M USD |
| Interest income | 98.91K USD | — | — | — | — |
| Interest expense | — | 165.67K USD | 3.46M USD | 10.25K USD | 24.37K USD |
| Depreciation and amortization | — | — | — | 7.05M USD | 2.15M USD |
| Operating income | −10.49M USD | −8.02M USD | −8.53M USD | −7.05M USD | −2.15M USD |
| Net income | −10.44M USD | −7.85M USD | −11.98M USD | −7.06M USD | −2.18M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 44%
- 4 beats, 4 misses, 1 met estimate
- Average EPS surprise
- -28.88%
- 9 comparable reports
- Latest EPS result
- -0.03
EPS: actual versus estimate
Recent quarterly results
MIRA news
MIRA peers
ETFs holding MIRA
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 312.11K
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
Vanguard Extended Market ETFVXF- Market value
- 281.56K
- Weight
- 0.00%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $245.53+0.82%
iShares Micro-Cap ETFIWC- Market value
- 91.09K
- Weight
- 0.01%
- AUM
- 1.53B USD
- Expense ratio
- 0.60%
- Price / 1D
- $198.39+1.10%
Continue in GoAI
Research MIRAresearch.disclaimer